Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Endocyte
West Lafayette, Indiana, United States
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Endocyte developed targeted therapies for cancer, focusing on small molecule drug conjugates and radioligand therapies. Its lead asset, ^177Lu‑PSMA‑617, showed promising results in metastatic castration-resistant prostate cancer and was in Phase III trials at the time of its acquisition by Novartis. Earlier programs included SMDCs targeting folate receptors and PSMA with both therapeutic and imaging applications. The company’s platforms enabled direct delivery of cytotoxic or radioactive payloads to tumor cells while sparing healthy tissue. Clinical data indicated significant reductions in disease biomarkers among treated patients.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drug conjugates (SMDCs)Radioligand therapies (RLT)Targeted therapeutics using folate and PSMA ligands
- Industry
- Biotech
02
Partnerships
ABX GmbH — licensed rights to ^177Lu‑PSMA‑617 from ABX GmbH in Germany
Beyond the preview
Go deeper on Endocyte.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endocyte.